PT3357511T - Inibidores da ativação de células t - Google Patents

Inibidores da ativação de células t

Info

Publication number: PT3357511T
Authority: PT; Portugal
Prior art keywords: inhibitors; cell activation; activation; cell
Prior art date: 2011-06-30

Application number

PT181517186T

Other languages

English (en)

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-06-30

Filing date

2012-06-29

Publication date

2020-07-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47424568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3357511(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-06-29 Application filed by Genzyme Corp filed Critical Genzyme Corp

2020-07-23 Publication of PT3357511T publication Critical patent/PT3357511T/pt

Links

230000006044 T cell activation Effects 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Cell Biology (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)

PT181517186T 2011-06-30 2012-06-29 Inibidores da ativação de células t PT3357511T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161503282P	2011-06-30	2011-06-30

Publications (1)

Publication Number	Publication Date
PT3357511T true PT3357511T (pt)	2020-07-23

Family

ID=47424568

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT181517186T PT3357511T (pt)	2011-06-30	2012-06-29	Inibidores da ativação de células t
PT12804528T PT2726101T (pt)	2011-06-30	2012-06-29	Inibidores da ativação de células t

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT12804528T PT2726101T (pt)	2011-06-30	2012-06-29	Inibidores da ativação de células t

Country Status (34)

Country	Link
US (3)	US9834604B2 (pt)
EP (2)	EP3357511B1 (pt)
JP (4)	JP6157461B2 (pt)
KR (1)	KR20140058532A (pt)
CN (2)	CN107988156B (pt)
AU (3)	AU2012275133B2 (pt)
BR (1)	BR112013033661A2 (pt)
CA (1)	CA2839462A1 (pt)
CL (1)	CL2013003725A1 (pt)
CO (1)	CO6841996A2 (pt)
CR (1)	CR20130661A (pt)
DK (2)	DK3357511T3 (pt)
DO (1)	DOP2013000313A (pt)
ES (2)	ES2694749T3 (pt)
GT (1)	GT201300323A (pt)
HK (1)	HK1258401A1 (pt)
HR (1)	HRP20181786T1 (pt)
HU (1)	HUE040455T2 (pt)
LT (1)	LT2726101T (pt)
MA (1)	MA35280B1 (pt)
MX (1)	MX354922B (pt)
MY (1)	MY180616A (pt)
NI (1)	NI201300140A (pt)
PE (1)	PE20141469A1 (pt)
PL (2)	PL3357511T3 (pt)
PT (2)	PT3357511T (pt)
RS (1)	RS57996B1 (pt)
RU (1)	RU2657440C2 (pt)
SG (1)	SG10201604715VA (pt)
SI (1)	SI2726101T1 (pt)
TN (1)	TN2013000532A1 (pt)
UA (1)	UA116191C2 (pt)
WO (1)	WO2013003761A1 (pt)
ZA (1)	ZA201309532B (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2647707B1 (en)	2010-11-30	2018-09-12	Chugai Seiyaku Kabushiki Kaisha	Cytotoxicity-inducing therapeutic agent
PT3357511T (pt) *	2011-06-30	2020-07-23	Genzyme Corp	Inibidores da ativação de células t
US8956619B2 (en) *	2011-10-25	2015-02-17	University Of Maryland, Baltimore County	Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
EP2931949B1 (en)	2012-12-11	2019-09-18	Albert Einstein College of Medicine	Methods for high throughput receptor/ligand identification
GB201311487D0 (en) *	2013-06-27	2013-08-14	Alligator Bioscience Ab	Bispecific molecules
MX2016012552A (es)	2014-04-07	2017-01-09	Chugai Pharmaceutical Co Ltd	Molecula ligada a antigeno inmunoactivada.
BR112016026299A2 (pt) *	2014-05-13	2018-02-20	Chugai Seiyaku Kabushiki Kaisha	molécula de ligação ao antígeno redirecionado à célula t para células tendo função de imunossupressão
TWI693232B (zh)	2014-06-26	2020-05-11	美商宏觀基因股份有限公司	與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
CN105296433B (zh)	2014-08-01	2018-02-09	中山康方生物医药有限公司	一种ctla4抗体、其药物组合物及其用途
JO3663B1 (ar)	2014-08-19	2020-08-27	Merck Sharp & Dohme	الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
AU2015360502A1 (en)	2014-12-10	2017-06-29	Regents Of The University Of Minnesota	Genetically modified cells, tissues, and organs for treating disease
CN104459129A (zh) *	2015-01-05	2015-03-25	复旦大学附属华山医院	一种鉴别活动性与潜伏性结核分枝杆菌感染的诊断试剂盒
US11319359B2 (en)	2015-04-17	2022-05-03	Alpine Immune Sciences, Inc.	Immunomodulatory proteins with tunable affinities
TWI773646B (zh)	2015-06-08	2022-08-11	美商宏觀基因股份有限公司	結合lag-3的分子和其使用方法
MD3456346T2 (ro)	2015-07-30	2021-11-30	Macrogenics Inc	Molecule de legare la PD-1 și LAG-3 și metode de utilizare a acestora
BR112018004965A2 (pt) *	2015-09-14	2018-10-09	Alpine Immune Sciences Inc	domínios de superfamìlia de imunoglobulina variante ajustàvel
CR20180306A (es)	2015-11-02	2018-10-16	Five Prime Therapeutics Inc	Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer
JP6931329B2 (ja)	2015-11-18	2021-09-01	中外製薬株式会社	免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
US11649293B2 (en)	2015-11-18	2023-05-16	Chugai Seiyaku Kabushiki Kaisha	Method for enhancing humoral immune response
CN108367069B (zh)	2015-12-14	2022-08-23	宏观基因有限公司	对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
KR101918456B1 (ko) *	2015-12-15	2018-11-16	앱클론(주)	Cd80 및 cd86에 특이적으로 결합하는 항체
CA3008244A1 (en)	2015-12-16	2017-06-22	Merck Sharp & Dohme Corp.	Anti-lag3 antibodies and antigen-binding fragments
EP3192805A1 (en)	2016-01-15	2017-07-19	Humanitas Mirasole S.p.A.	Inhibitors of t cell activation or stimulation and uses thereof
US20190062400A1 (en) *	2016-03-02	2019-02-28	Cue Biopharma, Inc.	T-cell modulatory multimeric polypeptides and methods of use thereof
EP3443123B1 (en) *	2016-04-11	2021-08-11	Board of Regents, The University of Texas System	Methods and compositions for detecting single t cell receptor affinity and sequence
KR102536850B1 (ko)	2016-04-15	2023-05-26	알파인 이뮨 사이언시즈, 인코포레이티드	Icos 리간드 변이체 면역조절 단백질 및 그의 용도
AU2017248830B2 (en)	2016-04-15	2023-03-09	Alpine Immune Sciences, Inc.	CD80 variant immunomodulatory proteins and uses thereof
US11505591B2 (en)	2016-05-18	2022-11-22	Cue Biopharma, Inc.	T-cell modulatory multimeric polypeptides and methods of use thereof
JP2019522466A (ja)	2016-05-18	2019-08-15	アルバートアインシュタインカレッジオブメディシン，インコーポレイティド	変異ｐｄ−ｌ１ポリペプチド、ｔ細胞調節多量体ポリペプチド、及びそれらの使用方法
US11471488B2 (en)	2016-07-28	2022-10-18	Alpine Immune Sciences, Inc.	CD155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en)	2016-07-28	2018-02-01	Alpine Immune Sciences, Inc.	Cd112 variant immunomodulatory proteins and uses thereof
WO2018035710A1 (en)	2016-08-23	2018-03-01	Akeso Biopharma, Inc.	Anti-ctla4 antibodies
IL266696B2 (en)	2016-12-22	2023-04-01	Cue Biopharma Inc	Multimeric polypeptides modulate t cells and methods for their use
EP3565829A4 (en)	2017-01-09	2021-01-27	Cue Biopharma, Inc.	MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
JP2020514375A (ja)	2017-03-15	2020-05-21	キューバイオファーマ，インコーポレイテッド	免疫応答を調節するための方法
CA3053812A1 (en)	2017-03-16	2018-09-20	Alpine Immune Sciences, Inc.	Pd-l2 variant immunomodulatory proteins and uses thereof
EP3596114A2 (en)	2017-03-16	2020-01-22	Alpine Immune Sciences, Inc.	Cd80 variant immunomodulatory proteins and uses thereof
ES2899616T3 (es)	2017-04-28	2022-03-14	Five Prime Therapeutics Inc	Polipéptidos del dominio extracelular del CD80 para su uso en aumentar los linfocitos T de memoria central
MA50360A (fr)	2017-10-10	2020-08-19	Alpine Immune Sciences Inc	Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations
BR112020007542A2 (pt)	2017-10-18	2020-12-01	Alpine Immune Sciences, Inc.	proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados
WO2019106435A1 (en) *	2017-11-29	2019-06-06	Uti Limited Partnership	Methods of treating autoimmune disease
CN108003238B (zh) *	2017-11-30	2021-02-02	常州费洛斯药业科技有限公司	一种能特异识别ctla-4的全人源单克隆抗体或抗体片段及其方法和用途
EP3737689A4 (en)	2018-01-09	2021-12-01	Cue Biopharma, Inc.	MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
WO2019151392A1 (ja)	2018-01-31	2019-08-08	国立大学法人東北大学	抗原特異的ｍｈｃ発現調節法
MX2020012124A (es) *	2018-05-14	2021-04-19	Immunocore Ltd	Polipeptidos de unión bifuncional.
US12065476B2 (en)	2018-06-15	2024-08-20	Alpine Immune Sciences, Inc.	PD-1 variant immunomodulatory proteins and uses thereof
MX2022005999A (es) *	2019-11-20	2022-06-17	Gi Cell Inc	Composicion de medio para el cultivo de linfocitos t y metodo para el cultivo de linfocitos t mediante el uso de la misma.
IL296209A (en)	2020-05-12	2022-11-01	Cue Biopharma Inc	Multimeric t-cell modulatory polypeptides and methods of using them
WO2022056014A1 (en)	2020-09-09	2022-03-17	Cue Biopharma, Inc.	Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
EP4255929A2 (en)	2020-12-02	2023-10-11	Vib Vzw	An ltbr agonist in combination therapy against cancer
CN114805591A (zh) *	2022-03-31	2022-07-29	浙江大学	靶向ctla-4及配体cd80或cd86的双特异性抗体、筛选方法、组合物及应用
WO2024036287A1 (en) *	2022-08-12	2024-02-15	Abata Therapeutics, Inc.	Stable regulatory t cells and methods of production

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5149782A (en)	1988-08-19	1992-09-22	Tanox Biosystems, Inc.	Molecular conjugates containing cell membrane-blending agents
US5108921A (en)	1989-04-03	1992-04-28	Purdue Research Foundation	Method for enhanced transmembrane transport of exogenous molecules
AU8507191A (en)	1990-08-29	1992-03-30	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
WO1993011161A1 (en)	1991-11-25	1993-06-10	Enzon, Inc.	Multivalent antigen-binding proteins
DE69329974T2 (de)	1992-12-04	2001-07-19	Medical Research Council, London	Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
WO1994026087A2 (en)	1993-05-14	1994-11-24	Connor Kim C O	Recombinant protein production and insect cell culture and process
US5429746A (en)	1994-02-22	1995-07-04	Smith Kline Beecham Corporation	Antibody purification
UA71889C2 (uk)	1996-04-02	2005-01-17	Йєда Рісерч Енд Дівелопмент Ко. Лтд.	Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування
CA2273080C (fr)	1996-11-28	2004-11-09	Institut Gustave Roussy	Mutants de la proteine lag-3, leur expression et utilisation
US7829084B2 (en)	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
DE60237282D1 (de)	2001-06-28	2010-09-23	Domantis Ltd	Doppelspezifischer ligand und dessen verwendung
GB0216648D0 (en)	2002-07-18	2002-08-28	Lonza Biologics Plc	Method of expressing recombinant protein in CHO cells
EP1452868A2 (en)	2003-02-27	2004-09-01	Pepscan Systems B.V.	Method for selecting a candidate drug compound
WO2004076488A1 (en) *	2003-02-27	2004-09-10	Theravision Gmbh	A molecule which binds cd80 and cd86
PT1897548E (pt) *	2003-02-28	2013-11-19	Univ Johns Hopkins	Regulação de células t
CA2566473A1 (en) *	2004-05-17	2005-12-08	Board Of Trustees Of The University Of Illinois	Uses of bispecific antibody (biab) coated dendritic cells pulsed with antigens
US20090252741A1 (en) *	2004-09-08	2009-10-08	Ohio State University Research Foundation	Human monoclonal anti-ctla4 antibodies in cancer treatment
MX2007002942A (es) *	2004-09-13	2008-03-05	Genzyme Corp	Constructos multimericos.
PT1844337E (pt)	2005-01-24	2014-04-03	Pepscan Systems Bv	Compostos ligantes, compostos imunogénicos e peptidomiméticos
WO2008073160A2 (en) *	2006-08-17	2008-06-19	The Trustees Of Columbia University In The City Of New York	Methods for converting or inducing protective immunity
WO2008157367A1 (en)	2007-06-15	2008-12-24	Genzyme Corporation	Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
EP2240204A1 (en) *	2008-02-04	2010-10-20	Medarex, Inc.	Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
PT2257624E (pt)	2008-02-05	2012-05-29	Medical Res Council	Métodos e composições
WO2009105669A2 (en)	2008-02-20	2009-08-27	Genzyme Corporation	Angiogenesis inhibition
AR072999A1 (es) *	2008-08-11	2010-10-06	Medarex Inc	Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
GB0913775D0 (en)	2009-08-06	2009-09-16	Medical Res Council	Multispecific peptides
PT3357511T (pt)	2011-06-30	2020-07-23	Genzyme Corp	Inibidores da ativação de células t

2012
- 2012-06-29 PT PT181517186T patent/PT3357511T/pt unknown
- 2012-06-29 PE PE2013002910A patent/PE20141469A1/es active IP Right Grant
- 2012-06-29 PL PL18151718T patent/PL3357511T3/pl unknown
- 2012-06-29 RS RS20181350A patent/RS57996B1/sr unknown
- 2012-06-29 EP EP18151718.6A patent/EP3357511B1/en active Active
- 2012-06-29 MX MX2013015384A patent/MX354922B/es active IP Right Grant
- 2012-06-29 UA UAA201400833A patent/UA116191C2/uk unknown
- 2012-06-29 WO PCT/US2012/045017 patent/WO2013003761A1/en active Application Filing
- 2012-06-29 ES ES12804528.3T patent/ES2694749T3/es active Active
- 2012-06-29 PT PT12804528T patent/PT2726101T/pt unknown
- 2012-06-29 CN CN201711283703.XA patent/CN107988156B/zh active Active
- 2012-06-29 SI SI201231438T patent/SI2726101T1/sl unknown
- 2012-06-29 LT LTEP12804528.3T patent/LT2726101T/lt unknown
- 2012-06-29 DK DK18151718.6T patent/DK3357511T3/da active
- 2012-06-29 US US14/128,461 patent/US9834604B2/en active Active
- 2012-06-29 DK DK12804528.3T patent/DK2726101T3/en active
- 2012-06-29 BR BR112013033661A patent/BR112013033661A2/pt not_active Application Discontinuation
- 2012-06-29 MY MYPI2013004609A patent/MY180616A/en unknown
- 2012-06-29 KR KR1020147002646A patent/KR20140058532A/ko not_active Application Discontinuation
- 2012-06-29 SG SG10201604715VA patent/SG10201604715VA/en unknown
- 2012-06-29 JP JP2014519165A patent/JP6157461B2/ja active Active
- 2012-06-29 RU RU2014102956A patent/RU2657440C2/ru not_active IP Right Cessation
- 2012-06-29 CN CN201280042085.9A patent/CN103796681B/zh active Active
- 2012-06-29 PL PL12804528T patent/PL2726101T3/pl unknown
- 2012-06-29 CA CA2839462A patent/CA2839462A1/en not_active Abandoned
- 2012-06-29 HU HUE12804528A patent/HUE040455T2/hu unknown
- 2012-06-29 ES ES18151718T patent/ES2810424T3/es active Active
- 2012-06-29 EP EP12804528.3A patent/EP2726101B1/en active Active
- 2012-06-29 AU AU2012275133A patent/AU2012275133B2/en not_active Ceased
2013
- 2013-12-13 CR CR20130661A patent/CR20130661A/es unknown
- 2013-12-18 ZA ZA2013/09532A patent/ZA201309532B/en unknown
- 2013-12-19 NI NI201300140A patent/NI201300140A/es unknown
- 2013-12-26 DO DO2013000313A patent/DOP2013000313A/es unknown
- 2013-12-26 GT GT201300323A patent/GT201300323A/es unknown
- 2013-12-26 TN TNP2013000532A patent/TN2013000532A1/fr unknown
- 2013-12-26 CL CL2013003725A patent/CL2013003725A1/es unknown
- 2013-12-27 CO CO13301377A patent/CO6841996A2/es unknown
2014
- 2014-01-22 MA MA36702A patent/MA35280B1/fr unknown
2017
- 2017-03-08 JP JP2017043440A patent/JP6530436B2/ja active Active
- 2017-10-19 US US15/788,433 patent/US11028170B2/en active Active
- 2017-11-15 AU AU2017261541A patent/AU2017261541B2/en not_active Ceased
2018
- 2018-10-30 HR HRP20181786TT patent/HRP20181786T1/hr unknown
2019
- 2019-01-17 HK HK19100808.1A patent/HK1258401A1/zh unknown
- 2019-05-15 JP JP2019091790A patent/JP6826154B2/ja active Active
- 2019-09-09 AU AU2019226276A patent/AU2019226276B2/en not_active Expired - Fee Related
2021
- 2021-01-14 JP JP2021003877A patent/JP2021073216A/ja active Pending
- 2021-05-03 US US17/306,509 patent/US12043665B2/en active Active

Also Published As

Publication number	Publication date
SG10201604715VA (en)	2016-07-28
JP6530436B2 (ja)	2019-06-12
JP6826154B2 (ja)	2021-02-03
CA2839462A1 (en)	2013-01-03
US11028170B2 (en)	2021-06-08
EP2726101B1 (en)	2018-08-08
WO2013003761A1 (en)	2013-01-03
UA116191C2 (uk)	2018-02-26
PE20141469A1 (es)	2014-10-31
HK1258401A1 (zh)	2019-11-08
DK3357511T3 (da)	2020-08-03
CN107988156A (zh)	2018-05-04
US20180030134A1 (en)	2018-02-01
AU2019226276B2 (en)	2021-11-11
AU2012275133A1 (en)	2014-01-16
BR112013033661A2 (pt)	2017-01-24
CN103796681B (zh)	2018-07-20
MY180616A (en)	2020-12-03
AU2017261541B2 (en)	2019-10-03
HUE040455T2 (hu)	2019-03-28
RU2657440C2 (ru)	2018-06-13
MA35280B1 (fr)	2014-07-03
PT2726101T (pt)	2018-11-21
ZA201309532B (en)	2014-08-27
EP3357511B1 (en)	2020-05-13
AU2019226276A1 (en)	2019-09-26
GT201300323A (es)	2015-02-12
CN103796681A (zh)	2014-05-14
EP3357511A1 (en)	2018-08-08
RU2014102956A (ru)	2015-08-10
CL2013003725A1 (es)	2014-07-25
US9834604B2 (en)	2017-12-05
US20210380686A1 (en)	2021-12-09
JP2019151656A (ja)	2019-09-12
CN107988156B (zh)	2022-01-04
PL3357511T3 (pl)	2020-11-16
EP2726101A4 (en)	2015-01-28
JP2014522846A (ja)	2014-09-08
US12043665B2 (en)	2024-07-23
LT2726101T (lt)	2018-11-26
AU2012275133B2 (en)	2017-08-17
EP2726101A1 (en)	2014-05-07
MX2013015384A (es)	2014-10-13
ES2694749T3 (es)	2018-12-27
TN2013000532A1 (en)	2015-03-30
CR20130661A (es)	2014-04-15
HRP20181786T1 (hr)	2019-02-08
CO6841996A2 (es)	2014-01-20
PL2726101T3 (pl)	2019-01-31
RS57996B1 (sr)	2019-01-31
NZ619473A (en)	2015-06-26
JP6157461B2 (ja)	2017-07-05
DOP2013000313A (es)	2014-07-15
JP2017128585A (ja)	2017-07-27
KR20140058532A (ko)	2014-05-14
ES2810424T3 (es)	2021-03-08
MX354922B (es)	2018-03-26
SI2726101T1 (sl)	2018-12-31
US20140348832A1 (en)	2014-11-27
AU2017261541A1 (en)	2017-12-07
JP2021073216A (ja)	2021-05-13
NI201300140A (es)	2014-06-26
DK2726101T3 (en)	2018-12-03

Publication	Publication Date	Title
HK1258401A1 (zh)	2019-11-08	T細胞活化的抑制劑
EP2683693A4 (en)	2014-10-08	ROR-GAMMA-T INHIBITORS
TWI560172B (en)	2016-12-01	Neprilysin inhibitors
ZA201303433B (en)	2014-12-23	Inhibitors of hiv replication
EP2678018A4 (en)	2015-09-30	COMBINATION OF CHINESE HEMMER AND USES THEREOF
EP2734529A4 (en)	2015-06-03	BTK INHIBITORS
HK1198827A1 (en)	2015-06-12	Dyrk1 inhibitors and uses thereof dyrk1
EP2785183A4 (en)	2015-07-01	TRIAZOLOPYRIDINONE PDE10 INHIBITORS
ZA201206456B (en)	2013-05-29	Uses of dgati inhibitors
EP2776393A4 (en)	2015-05-27	NAMPT INHIBITORS
IL231269A0 (en)	2014-04-30	Preparations for the treatment of HIV
HK1199252A1 (en)	2015-06-26	Inhibitors of nedd8-activating enzyme nedd8-
EP2521451A4 (en)	2013-08-21	INHIBITORS OF THE HEDGEHOG PATH
EP2688901A4 (en)	2015-04-15	INHIBITORS OF 17SS-HSD1, 17SS-HSD3 AND 17SS-HSD10
HK1201066A1 (en)	2015-08-21	Pyranopyridone inhibitors of tankyrase
PL2888228T3 (pl)	2019-10-31	Inhibitory oddziaływania CD40-TRAF6
EP2663322A4 (en)	2014-06-25	NEW USES OF CYCLOPHILIN INHIBITORS
GB201120474D0 (en)	2012-01-11	Inhibitors
GB201104399D0 (en)	2011-04-27	Novel inhibitors
GB201018597D0 (en)	2010-12-22	Inhibitors
GB201006605D0 (en)	2010-06-02	Novel inhibitors
GB201003936D0 (en)	2010-04-21	Novel inhibitors
GB201003502D0 (en)	2010-04-14	Novel inhibitors